 GENT, Belgium and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 09, 2020 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Fujirebio Europe announced today to have entered a partnership to leverage LUMIPULSE G technology for large-scale COVID-19 antigen testing with further deployment in German airports. 